New drug combo targets Gene-Mutated breast cancer in japanese patients
NCT ID NCT04524000
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 27 times
Summary
This study tests a combination of two drugs, alpelisib and fulvestrant, in Japanese men and postmenopausal women with a certain type of advanced breast cancer (HR+, HER2-) that has a PIK3CA gene change and has stopped responding to hormone therapy. The goal is to see if the combination is safe and effective at shrinking tumors. About 24 participants will receive the treatment, and researchers will monitor side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Nagoya, Aichi-ken, 464 8681, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4668560, Japan
-
Novartis Investigative Site
Nagoya, Aichi-ken, 4678602, Japan
-
Novartis Investigative Site
Kashiwa, Chiba, 277-8577, Japan
-
Novartis Investigative Site
Isehara, Kanagawa, 259-1193, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 241-8515, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 9808574, Japan
-
Novartis Investigative Site
Osaka, Osaka, 5400006, Japan
-
Novartis Investigative Site
Osaka, Osaka, 5418567, Japan
-
Novartis Investigative Site
Suita, Osaka, 565-0871, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 1138677, Japan
-
Novartis Investigative Site
Koto Ku, Tokyo, 135-8550, Japan
-
Novartis Investigative Site
Meguro-ku, Tokyo, 152-8902, Japan
-
Novartis Investigative Site
Kumamoto, 860-8556, Japan
-
Novartis Investigative Site
Niigata, 951-8566, Japan
Conditions
Explore the condition pages connected to this study.